STAAR Surgical Co. - 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended October 1, 1999, and the nine-month period ended on that date. STAAR Surgical Company is a Delaware corporation headquartered in Monrovia, California, specializing in refractive products including the Implantable Contact Lens (ICL) and intraocular lenses (IOLs). The company operates internationally with significant sales in Europe.
Key Financial Metrics
| Metric | Nine Months Ended Oct 1, 1999 | Nine Months Ended Oct 2, 1998 |
|---|---|---|
| Total Revenues | $43,381,179 | $40,985,219 |
| Gross Profit | $27,170,154 | $28,295,350 |
| Operating Income | $4,200,562 | $6,835,703 |
| Net Income | $1,876,798 | $1,915,573 |
| Cash and Equivalents (End of Period) | $3,718,583 | $3,239,734 |
| Total Debt (Current + Long-term) | $14,267,087 | $11,333,562 |
| Current Ratio | 3.0:1 | 2.9:1 (Jan 1, 1999) |
Margins: Gross margin decreased to 62.6% from 69.0% in the prior year. Net income margin was 4.3% compared to 4.7% in the prior year.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 5.8% year-over-year, driven by sales of refractive products (ICL, Toric IOL) and a new subsidiary, Laser and Implant Technology Centers (LITC). This was partially offset by lower average selling prices for IOLs due to competition.
- Margin Compression: Cost of sales rose to 37.4% of revenue from 31.0%. This was attributed to lower selling prices, higher unit costs for inventory produced in 1998, a product mix shift to higher-cost three-piece lenses, and the introduction of custom surgical supply packs.
- Operating Expenses: Total selling, general, and administrative expenses increased 7.0%. Research and development expenses rose 11.1% due to clinical trial management costs.
- Profitability: Operating income declined 44.1% to $4.2 million, and income before taxes dropped 44.1% to $3.5 million. Net income remained relatively flat at $1.9 million, though the prior year included a one-time write-off of start-up costs ($1.68 million) which is absent in the current period.
- Liquidity: Cash and cash equivalents decreased by approximately $1.0 million from the beginning of the fiscal year. Net cash provided by operating activities was $320,120, a significant decrease from $1.55 million in the prior year, primarily due to a $4.0 million increase in operating working capital (inventory and prepaids).
Guidance, Outlook, and Risks
- Outlook: Management expects to continue to be profitable and believes future cash flow needs will be met by operations or additional financing if required.
- Capital Structure: The company renegotiated its credit facility, supplementing a $10 million line-of-credit with a $4 million term note.
- Year 2000 Compliance: The company is ahead of schedule for Y2K compliance. Internal systems are certified, and costs incurred to date are immaterial. However, risks remain regarding the continuity of services from external vendors and utilities.
- International Risks: Foreign sales (approx. 50% of total) expose the company to exchange rate fluctuations, export/import duties, and political instability.
Investor Verification Checklist
- Verify the sustainability of revenue growth given the noted decline in average selling prices for IOLs.
- Monitor inventory levels ($22.1 million) and working capital trends, as these significantly impacted operating cash flow.
- Assess the impact of the new $4 million term note on future interest expense and debt covenants.
- Confirm the status of Year 2000 compliance for critical third-party vendors and suppliers.
- Review the performance of the new subsidiary, Laser and Implant Technology Centers (LITC), as a growth driver.